"The Institute for Neurodegenerative Disorders (IND), founded in 2001, is an independent 501(c)3 nonprofit research institute based in New Haven, Connecticut. Its team of expert researchers includes neurologists, nurses, study coordinators, neuropsychologists, and nuclear medicine technologists working together to accomplish IND’s mission. We envision a future in which research provides methods of early detection and effective treatment and ultimately the prevention of these neurologic conditions."

During the past decade, Institute for Neurodegenerative Disorders conducted 25 clinical trials. In the 10-year time frame, 25 clinical trials started and 13 clinical trials were completed, i.e. on average, 52% percent of trials that started reached the finish line to date. In the past 5 years, 15 clinical trials started and 10 clinical trials were completed. i.e. 66.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Institute for Neurodegenerative Disorders" #1 sponsor was "Institute for Neurodegenerative Disorders" with 35 trials, followed by "Eli Lilly and Company" with 8 trials sponsored, "Michael J. Fox Foundation for Parkinson's Research" with 4 trials sponsored, "AstraZeneca" with 3 trials sponsored and "Hoffmann-La Roche" with 3 trials sponsored. Other sponsors include 20 different institutions and companies that sponsored additional 25 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Institute for Neurodegenerative Disorders" #1 collaborator was "Molecular NeuroImaging" with 12 trials as a collaborator, "United States Department of Defense" with 7 trials as a collaborator, "National Institute of Neurological Disorders and Stroke (NINDS)" with 4 trials as a collaborator, "The Parkinson Study Group" with 4 trials as a collaborator and "Eli Lilly and Company" with 3 trials as a collaborator. Other collaborators include 25 different institutions and companies that were collaborators in the rest 27 trials.

According to Clinical.Site data, the most researched conditions in "Institute for Neurodegenerative Disorders" are "Parkinson Disease" (24 trials), "Alzheimer Disease" (19 trials), "Alzheimer's Disease" (16 trials), "Parkinsonian Syndrome" (8 trials) and "Parkinson's Disease" (6 trials). Many other conditions were trialed in "Institute for Neurodegenerative Disorders" in a lesser frequency.

Most popular intervention types in "Institute for Neurodegenerative Disorders" are "Drug" (70 trials), "Procedure" (3 trials), "Diagnostic Test" (2 trials), "Other" (2 trials) and "Behavioral" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (17 trials), "LY3372689" (3 trials), "Lanabecestat" (3 trials), "Aducanumab" (2 trials) and "Bapineuzumab 0.5 mg/kg" (2 trials). Other intervention names were less common.

The vast majority of trials in "Institute for Neurodegenerative Disorders" are 78 trials for "All" genders.

Currently, there are NaN active trials in "Institute for Neurodegenerative Disorders". undefined are not yet recruiting, 4 are recruiting, 7 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 41 completed trials in Institute for Neurodegenerative Disorders, undefined suspended trials, and 24 terminated clinical trials to date.

Out of the total trials that were conducted in Institute for Neurodegenerative Disorders, 23 "Phase 1" clinical trials were conducted, 20 "Phase 2" clinical trials and 23 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".